Portal de Periódicos da CAPES

Sandoz boosts Austria antibiotics

2022; American Chemical Society; Volume: 100; Issue: 40 Linguagem: Inglês

10.1021/cen-10040-buscon17

2474-7408

Rick Mullin,

Pharmaceutical Economics and Policy

Sandoz says it will invest $50 million to expand production capacity for finished-dosage penicillin at its plant in Kundl, Austria. The company, a leading supplier of generic and biosimilar medicines, last year announced a $100 million investment in the site to manufacture the active pharmaceutical ingredient (API) in oral amoxicillin. The investments are part of Sandoz’s $250 million expansion in antibiotics manufacturing at its European sites, including a $50 million project unveiled in 2021 to bolster sterile API production in Palafolls, Spain.